IONS Stock Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.77 |
| 52 Week High | US$54.44 |
| 52 Week Low | US$35.95 |
| Beta | 0.41 |
| 1 Month Change | -7.62% |
| 3 Month Change | -12.27% |
| 1 Year Change | -8.26% |
| 3 Year Change | 8.08% |
| 5 Year Change | -39.33% |
| Change since IPO | 287.70% |
Recent News & Updates
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09
Recent updates
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
Jun 15Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Apr 06Ionis Pharmaceuticals: Finding Financial Value In Biotech Research
Mar 27Ionis: At A Show-Me Crossroads
Mar 14Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates
Feb 25Shareholder Returns
| IONS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.0% | 0.6% | -0.6% |
| 1Y | -8.3% | 6.3% | 22.4% |
Return vs Industry: IONS underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: IONS underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| IONS volatility | |
|---|---|
| IONS Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IONS has not had significant price volatility in the past 3 months.
Volatility Over Time: IONS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 927 | Brett Monia | www.ionispharma.com |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| IONS fundamental statistics | |
|---|---|
| Market cap | US$5.48b |
| Earnings (TTM) | -US$384.77m |
| Revenue (TTM) | US$776.62m |
7.3x
P/S Ratio-14.7x
P/E RatioIs IONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IONS income statement (TTM) | |
|---|---|
| Revenue | US$776.62m |
| Cost of Revenue | US$924.31m |
| Gross Profit | -US$147.69m |
| Other Expenses | US$237.08m |
| Earnings | -US$384.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | -19.02% |
| Net Profit Margin | -49.54% |
| Debt/Equity Ratio | 610.5% |
How did IONS perform over the long term?
See historical performance and comparison